8 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 8 of 8 clinical reviews.
A prescriber-level guide to managing adverse events with triple receptor agonists (GLP-1/GIP/glucagon), including retatrutide. Covers GI toxicity, cardiovascular monitoring, hepatic considerations, and dose-titration protocols grounded in Phase 2/3 trial data.
A complete MD/PharmD-level guide to billing codes, prior authorization strategies, and prescribing essentials for GLP-1/GIP/glucagon triple agonists including retatrutide. Includes ICD-10, CPT, and appeal templates.
A prescriber-level monograph covering the pharmacology, clinical trial data, dosing considerations, and safety profile of GLP-1/GIP/glucagon triple agonists, with a focus on retatrutide and emerging agents in this drug class.
Complete DDI table, prescribing guide, and clinical pharmacology review for GLP-1/GIP/glucagon triple agonists including retatrutide. Written at MD/PharmD level with primary-source citations.
A prescriber-level guide to monitoring patients on GLP-1/GIP/glucagon triple agonists such as retatrutide, covering labs, imaging, dose titration safety checks, and adverse-event surveillance.
Clinician-focused review of prescribing triple agonists like retatrutide in special populations including renal impairment, hepatic disease, older adults, pregnancy, and adolescents.
A prescriber-level guide to titrating and tapering retatrutide and other GLP-1/GIP/glucagon triple agonists, including dose schedules, stopping rules, and restart protocols based on current trial data.
A clinical guide to selecting among GLP-1/GIP/glucagon triple agonists, including retatrutide and emerging agents, with dosing, trial data, and patient-selection frameworks for prescribers and dispensers.